Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the intergroup hepatoblastoma study p9645 as a part of the Children's Oncology Group

Cancer

Volumn 115, Issue 24, 2009, Pages 5828-5835

  Katzenstein, Howard M ^a   Chang, Kay W ^b   Krailo, Mark ^c   Chen, Zhengjia ^d   Finegold, Milton J ^e   Rowland, Jon ^f   Reynolds, Marleta ^g   Pappo, Alberto ^e   London, Wendy B ^h   Malogolowkin, Marcio ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h Children's Oncology Group Data Center ^*  (United States)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Amifostine; Hearing; Hepatoblastoma; Ototoxicity

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; VINCRISTINE;

ANEMIA; ARTICLE; BONE MARROW TOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEVER; HEARING LOSS; HEMOGLOBINURIA; HEPATOBLASTOMA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INCIDENCE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HEARING LOSS; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; MALE; RADIATION-PROTECTIVE AGENTS;

EID: 73149120511     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24667     Document Type: Article

References (20)

1. Douglass EC, Reynolds M, Finegold M, et al Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:96-99.
2. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991;9:2167-2176.
3. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050-1058.
4. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group phase II study. J Clin Oncol. 2002;20:3438-3444.
5. Dall'Igna P, Cecchetto G, Dominici C, et al. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: a discouraging pilot study. Med Pediatr Oncol. 2001;36:332-334.
6. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988;61:2192-2195.
7. Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. J Clin Oncol. 1993;11:1511-1516.
8. Malogolowkin M, Katzenstein HM, Krailo M, et al. Intensive versus standard platinum therapy for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645 [abstract]. Proc Am Soc Clin Oncol. 2004;23:799. Abstract 8516.
9. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841-847.
10. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445-2451.
11. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295-300.
12. Bishop YMM, Feinberg SE, Holland PMW. Discrete Multivariate Analysis. Cambridge, Mass: MIT Press; 1975.
13. Armitage P, Berry G. Statistical Methods in Medical Research. Palo Alto, Calif: Blackwell Scientific; 1998.
14. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons, Inc; 1980.
15. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol. 2006;24:2879-2884.
16. Koukourakis MI. Amifostine: is there evidence of tumor protection? Semin Oncol. 2003;30:18-30.
17. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
18. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784.
19. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24:188-191.
20. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008;26:3749-3755.